NEW YORK–(BUSINESS WIRE)–Nationally ranked litigation firm Labaton Sucharow announces investigation of Penumbra, Inc. (“Penumbra” Or The “Company”) (NYSE: PEN) and encourages investors with losses to contact the Firm. Penumbra, Inc. designs, develops, manufactures, and markets medical devices in the United States, Europe, Canada, Australia, Japan, and internationally.
The investigation focuses on whether Penumbra issued false and/or misleading statements and/or failed to disclose information pertinent to investors concerning the Company’s scientific research. On December 8, 2020, Quintessential Capital Management released a follow-up short report, alleging that some of the company’s scientific research pieces appear to have been authored by a fake individual. On this news the Company’s shares down over 15% during intraday trading on December 8, 2020.
If you are a current shareholder of Penumbra and you wish to learn more about your rights, please contact David J. Schwartz using the toll-free number (800) 321-0476 or via email at email@example.com.
About the Firm
Labaton Sucharow LLP is one of the world’s leading complex litigation firms representing clients in securities, antitrust, corporate governance and shareholder rights, and consumer cybersecurity and data privacy litigation. Labaton Sucharow has been recognized for its excellence by the courts and peers, and it is consistently ranked in leading industry publications. Offices are located in New York, NY, Wilmington, DE, and Washington, D.C. More information about Labaton Sucharow is available at http://www.labaton.com.